Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raised the price target from $25 to $30.
August 09, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has maintained a Buy rating on Catalyst Pharmaceuticals and raised the price target from $25 to $30.
The Buy rating and increased price target from a reputable analyst firm like Truist Securities is likely to positively impact investor sentiment and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100